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Abstract 
 
The oncostatin M receptor (OSMR) shows frequent gene copy-number gain and over-expression in 
cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells 
that overexpress OSMR, the major ligand OSM induces multiple pro-malignant effects, including 
invasion, secretion of angiogenic factors and metastasis. Here we demonstrate, for the first time, 
that OSMR over-expression in SCC cells activates cell-autonomous feed-forward signalling, via 
further expression of OSMR and OSM and sustained STAT3 activation despite expression of the 
negative regulator SOCS3. The pro-malignant effects associated with OSMR overexpression are 
critically mediated by JAK/STAT3 activation, which is induced by exogenous OSM and also by 
autocrine OSM:OSMR interactions. Importantly, specific inhibition of OSM:OSMR interactions by 
neutralizing antibodies significantly inhibits STAT3 activation and feed-forward signalling, leading to 
reduced invasion, angiogenesis and metastasis. Our findings are supported by data from 1,254 
clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, 
STAT3 and downstream targets. These data strongly support the development of OSM:OSMR 
blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical 
sites. 
 
Keywords: Cervix, head and neck, squamous cell carcinoma, oncostatin M receptor, neutralizing 
antibodies, metastasis, STAT3. 
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Introduction 
 
Many of the common human malignancies are squamous cell carcinomas (SCCs), in which tumour 
cells show features of squamous cell (keratinocyte) differentiation. High-risk human papillomavirus 
(HR-HPV) is a definite carcinogen for SCCs at multiple sites, including the cervix and head/neck [1]. 
Cervical carcinoma causes ~300,000 deaths p.a., while incidence rates of head/neck SCCs are rising 
rapidly [2]. There is an important need for new treatments in SCC and the recent success of 
antibody-based approaches in improving overall survival [3, 4] has strengthened the case for 
developing novel targeted therapies. 
 
Previous work has identified the oncostatin M receptor (OSMR) as a cell surface target suitable for 
antibody inhibition in cervical and other SCCs [5-7]. The OSMR gene is located on chromosome 5p, a 
genomic region that showed one of the highest rates of copy number gain in advanced cervical SCCs 
[8]. OSMR gain was seen in >60% of cervical SCCs (n=146 total) and was associated with significantly 
worse overall survival, producing a relative risk of death of 3.6 [8]. There was a significant correlation 
between OSMR gene copy number and OSMR transcript levels [9]. Importantly, high levels of OSMR 
associated with highly significant adverse overall survival in 251 cervical SCCs from The Cancer 
Genome Atlas (TCGA) (p=0.006) [9]. OSMR was also over-expressed in SCCs from multiple additional 
sites, including head/neck, skin and vulva [9], as well as in other common malignancies. The latter 
included breast adenocarcinoma [10], where high levels were associated with adverse clinical 
outcomes, and glioblastoma multiforme [11, 12]. 
 
OSMR is one of a group of receptors for cytokines of the interleukin-6 (IL6) family [13, 14]. It 
associates with gp130 to form a heterodimer that binds the major ligand oncostatin M (OSM) and 
also with gp130-like (GPL) protein to form a heterodimeric receptor for interleukin-31 (IL31). Human 
OSM (but not murine OSM) can also bind heterodimers of gp130 and leukemia inhibitory factor 
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receptor (LIFR), another IL6-family cytokine receptor [15]. OSM:OSMR interactions can activate 
multiple signalling pathways, leading to the transcription of a wide range of context-dependent 
target genes [14, 16]. We previously showed that OSM treatment of OSMR over-expressing cervical 
SCC cells exerted pro-malignant effects, including in vitro induction of cell migration/invasion, 
epithelial to mesenchymal transition (EMT) and secretion of pro-angiogenic factors; as well as 
increased experimental lung metastasis in vivo [5, 6, 9]. Key mediators of the observed effects 
included VEGFA, transglutaminase-2 (TGM2) and several EMT transcription factors, e.g. SNAI1 [5, 6, 
9]. In vivo, OSM is secreted by a variety of cell types in the tumour microenvironment, particularly 
macrophages and dendritic cells [13, 14]. 
 
In the present study, we dissected which signalling pathways mediated the multiple pro-malignant 
effects of OSM:OSMR interactions in SCC cells from the cervix and other sites, in order to determine 
the most rational strategies for therapeutic inhibition. Our data strongly support the development of 
OSM:OSMR blocking antibodies as biologically-targeted therapies against SCCs of the cervix and 
other anatomical sites. 
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Materials and Methods  
 
Cell culture 
 
The SCC cell lines used are listed in supplementary information, Table S1. For control samples, we 
used primary cultures of normal ectocervical epithelium (NCx6, NCx95, NCx96) from three 
hysterectomy specimens removed for non-neoplastic disease unrelated to the cervix [8]. The SCC 
cell lines selected for detailed in vitro analysis (CaSki, SW756, ME180, MS751, OSC19 and HSC1) 
were authenticated by short tandem repeat profiling (ATCC-LGC, Middlesex, UK).  
 
Recombinant human OSM (R&D Systems, Minneapolis, MN, USA) was added to cells at 10 ng/ml, in 
keeping with previous studies examining the effects of OSM in tissue culture [5, 17, 18]. For OSM 
pulse treatment, OSM was added for 15 min and cells washed twice with PBS before new medium 
was added. Recombinant human LIF and IL6 (R&D Systems) were used at up to 100 and 400 ng/ml, 
respectively. Secretion of OSM and IL6 was measured using human OSM DuoSet ELISA (R&D 
Systems) and Mini TMB ELISA (PeproTech, Rocky Hill, NJ, USA), respectively, normalizing for cell 
number. To neutralize exogenous OSM in vitro and in vivo, cells were treated with 0.25 μg/ml 
humanized IgG1 monoclonal anti-OSM antibody GSK2330811 (GlaxoSmithKline Stevenage, UK), 
unless otherwise specified, for 1 h prior to OSM treatment. To neutralize endogenous production of 
OSM and IL6, cells were pulsed for 15 min with OSM, washed twice with PBS, then treated with up 
to 1 μg/ml GlaxoSmithKline humanized anti-OSM antibody or 2.5 μg/ml anti-IL6 antibody (#500-P26, 
PeproTech) for between 1 and 24 h. Equal volumes of PBS (vehicle) or equal concentrations of a 
control humanized IgG antibody (Synagis, MedImmune, Cambridge, UK) were added to the cells as 
controls. 
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For signalling pathway inhibition, cells were pre-treated for 2 h with medium supplemented with 
TG101348 (Axon Medchem BV, Groningen, The Netherlands), Ruxolitinib (InvivoGen, Toulouse, 
France), S3I-201 (Sigma-Aldrich, St. Louis, USA), Stattic (Cayman Chemical Company, Ann Arbor, MI, 
USA), LY294002 HCl (StressMarq Biosciences Inc., Victoria, Canada), PD98059 (Cell Signaling 
Technology, Danvers, USA) or PP242 (Cayman Chemical Company). For each molecule, we chose the 
lowest concentration that inhibited the target pathway in SW756 cells and also caused no significant 
cytotoxicity in vitro. Control cells were treated with equivalent volumes of PBS or DMSO vehicle 
(vol/vol) only. Cell viability was assessed using an MTT assay (Sigma-Aldrich). 
 
Cell transfections 
 
For gene depletion, the targets OSMR, LIFR and STAT3 were each depleted using a 40 nM pool of 
four siRNAs (ON-TARGETplus SMARTpool L-008050, L-008017, L-003544, respectively; Dharmacon, 
Lafayette, LA, USA) and compared with cells treated with pooled non-targeting control (NTC) siRNAs 
(ON-TARGETplus Non-targeting Pool, D-001810-10-05, Dharmacon), as described [19]. OSM or PBS 
was added 24 h after transfection and cells were treated for a further 24 or 48 h. siRNA sequences 
are given in supplementary material, Table S2. 
 
To over-express OSMR, ME180 and MS751 cells were transiently transfected with 0.5 or 1 μg, 
respectively, of pcDNA3.1zeo-hOSMR plasmid [5]. Control transfections used an equivalent amount 
of empty pcDNA3.1zeo vector. For OSM over-expression, SW756 cells were stably transfected with 2 
μg of pUNO1-hOSM expression construct (InvivoGen). Control transfections used 2 μg of pUNO1-
mcs control vector. For in vivo experiments, bioluminescent SW756 cells were generated by stable 
transfection of pGL4.51 luciferase reporter vector (Promega, Southampton, UK). 
 
RT-qPCR, Western blotting, cell invasion and angiogenesis assays 
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Relative mRNA and DNA levels were measured using qPCRBIO SyGreen Mix (PCR Biosystems, 
London, UK) (supplementary material, Table S3). Reverse transcription was done using 1 μg total 
RNA and QuantiTect Reverse Transcription (Qiagen, Crawley, UK). Expression ratios were calculated 
using the comparative threshold cycle method [20], normalizing to three reference genes: HMBS, 
YWHAZ and RPL13A [21]. DNA ratios were normalized to the ACTB promoter, GAPDH promoter and 
myoglobin promoter. They were referenced to normal cervix tissue (NCx6), in which there was one 
copy of the OSMR gene per haploid genome. Copy number gain of OSMR was defined by DNA levels 
at least two-fold greater than the mean for NCx6. Western blotting was performed as described [6], 
using the antibodies listed in supplementary material, Table S4. Details of the cell invasion and 
angiogenesis assays are given in supplementary material, Materials and methods. 
 
In vivo experimental metastasis 
 
Bioluminescent SW756 cells (1 x 106 in 200 μl), subjected to different treatments, were injected into 
the lateral tail vein of 5–6-week old female NOD SCID (NOD.CB17-Prkdcscid/NcrCrl) mice (Charles 
River, Oxford, UK), using 29-gauge insulin needles. Growth of lung tumours was monitored non-
invasively using the Living Image 3.2 In Vivo Imaging Software (PerkinElmer, Waltham, MA, USA). 
Initial measurements were made 30 min after tail vein injection, to confirm equal cell access to the 
lungs, followed by serial whole-body imaging at weekly intervals. All mice were maintained in 
conventional cages within a specific pathogen-free animal facility. They were treated in strict 
accordance with guidelines from the Cambridge University Licence Review Committee and the UK 
Home Office. The data obtained using the In Vivo Imaging Software were confirmed by two 
independent methods, namely histology and qPCR measurement of human DNA levels in the mouse 
lung tissue at the end of the experiment. Details are given in supplementary material, Materials and 
methods. 
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Bioinformatics and statistical analysis 
 
We analysed mRNA levels of OSMR, EGFR, VEGFA, TGM2, OSM and STAT3 in the publically-available 
next-generation sequencing data of The Cancer Genome Atlas. Details of the bioinformatics used 
and the statistical analyses performed are given in Supplementary material, Materials and methods.  
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Results 
 
OSMR over-expression in SCC cells enhances responsiveness to OSM 
 
We first compared signalling responses to OSM pulse-stimulation in two SCC cell lines from the same 
tissue of origin (cervix) that had high or low levels of OSMR protein (SW756 and ME180, 
respectively) (supplementary material, Figure S1). Following pulsed OSM exposure (10 ng/ml for 15 
min) (supplementary material, Figure S2A), activated STAT3, STAT5, AKT and ERK1/2 were induced at 
higher signal intensity and for a longer duration in the OSMR high cells (SW756), compared with the 
OSMR low cells (ME180) (Figure 1A-B and supplementary material, Figure S2B). The SW756 cells 
showed very rapid and sustained activation of STAT3, which was detectable 15 min after the OSM 
pulse and lasted for up to 72 h. The intensity and duration of induction of total EGFR (which has 
recently been shown to contribute to OSMR signalling [12]), and STAT1 were also greater in SW756 
than in ME180, although there were no differences in levels of induction of the activated 
(phosphorylated) forms (Figure 1A-B). Despite its effects on total EGFR protein, OSM did not alter 
EGFR transcript levels in SW756 cells after 24 or 48 h of continuous treatment (supplementary 
material,Figure S2C). STAT3 was also rapidly activated by pulsed OSM treatment in head/neck and 
skin SCC cells identified as expressing high levels of OSMR (OSC19 and HSC1, respectively) 
(supplementary material, Figures S1 and S2D-E). The enhanced and sustained activation of STAT3 
and ERK in OSMR-high cervical SCC cells was also confirmed in two additional cell lines: CaSki and 
MS751, which show high and low OSMR levels respectively (supplementary material, Figure S1 and 
supplementary material, Figure S2F). 
 
For two SCC cell lines with low basal OSMR levels (ME180 and MS751), in which OSMR levels had 
been increased following transient transfection, phosphorylated STAT3 and phosphorylated ERK1/2 
were expressed at higher basal levels and showed increased intensity and duration of induction by 
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pulsed OSM (Figure 1C-D). In SW756 cells, activation of STAT3, STAT5, AKT and ERK1/2 by OSM was 
abrogated by depleting OSMR but not by depleting LIFR (Figure 1E and supplementary material, Fig 
S2L-M), indicating that OSM was acting solely through the over-expressed OSMR in these cells. LIFR 
is functional in SW756, as treatment with LIF induced STAT3 activation (supplementary material, Fig 
S2G). Interestingly, in low OSMR expressing ME180 cells, activation of STAT3 was partially abrogated 
by depleting LIFR but not by depleting OSMR (supplementary material, Figure S2H-I). 
 
In keeping with the differences in signalling pathway activation, we observed that genes previously 
shown to mediate OSM effects in OSMR-over-expressing SCC cells were only induced in the OSMR-
over-expressing cells (SW756 and CaSki) and not in cells without OSMR over-expression (MS751 and 
ME180) (Figure 2A). The genes tested were known mediators of OSM-induced invasion (TGM2), EMT 
(SNAI1), and the pro-angiogenic phenotype (VEGFA) [5, 6, 9]. All three genes were also induced in 
head/neck and skin SCC cells with high levels of OSMR (OSC19 and HSC1, respectively) 
(supplementary material, Figure 2J-K). Forced OSMR over-expression in MS751 following transient 
transfection was associated with significantly greater induction of all three genes by OSM (Figure 
2B). In all four OSMR over-expressing cell lines tested (SW756, CaSki, OSC19 and HSC1), activation of 
all three genes by OSM was reduced by depleting OSMR but not by depleting LIFR (Figure 2C-D and 
supplementary material, Figure S2L-M).  
 
JAK2 and STAT3 mediate the pro-malignant effects of OSM:OSMR interactions 
 
We used small molecule inhibitors and siRNAs to identify which of the multiple signalling pathways 
induced by OSM in OSMR over-expressing SCC cells were responsible for the pro-malignant effects 
observed (Figure 3 and supplementary material, Figure S3). In SW756, OSM induction of the pro-
malignant target genes VEGFA, SNAI1 and TGM2 was significantly reduced by each of two JAK 
inhibitors, ruxolitinib (JAK1 and JAK2 inhibitor) and TG101348 (selective JAK2 inhibitor) (Figure 3A-B 
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and supplementary material, Figure S3A-E). No significant effect on OSM induction of target genes 
was seen by inhibiting the ERK1/2 pathway with MEK inhibitor PD98059, or by inhibiting mTOR 
complex 1/2 with PP242. Inhibition of pAKT with PI3K inhibitor LY294002 reduced VEGFA basal levels 
and partially abrogated its induction by OSM. However, there were no significant effects on SNAI1 
and TGM2. In SW756 cells transfected to produce OSM constitutively (SW756-pOSM), both JAK 
inhibitors significantly reduced expression of all three OSMR target genes (Figure 3C and 
supplementary material, Figure S3F-G). 
 
Specific inhibition of the downstream JAK target STAT3 could not be achieved using small molecule 
inhibitors, as these also inhibited STAT5 (Supplementary Figure S3H-I). STAT3 depletion using siRNAs 
(supplementary material, Figure S3J-N) led to significant inhibition of OSM induction of pro-
malignant target genes in SW756, CaSki (both Figure 3D), OSC19 and HSC1 cells (both Figure 3E). In 
keeping with these observations, STAT3 depletion significantly inhibited the increased invasiveness 
induced by OSM in SW756 cells (Figure 3F). 
 
In SW756 cells treated with non-targeting control siRNAs (siNTC), OSM pre-treatment for 48 h 
induced a significant increase in lung colonization following tail vein injection, compared with PBS-
treated cells (Figure 3G-H and supplementary material, Figure S3O-R). In contrast, SW756 cells 
treated with STAT3 siRNA (siSTAT3) showed reduced lung colonization following OSM treatment. 
Interestingly, siSTAT3-treated SW756 cells also showed reduced lung colonization in the absence of 
OSM pre-treatment, compared with siNTC-treated SW756 cells in the absence of OSM pre-
treatment (Figure 3G-H). There were no histological differences in cell morphology or mitotic rate 
between the lung metastases seen in the different experimental groups. 
 
OSM induces a feed-forward loop in SCC cells, which prolongs STAT3 activation 
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We examined the kinetics of STAT3 phosphorylation responses at early time points following OSM 
pulse-stimulation of OSMR-overexpressing SCC cells (SW756). Strong induction was seen after 30 
min, followed by induction of SOCS3 (an inhibitor of STAT3 activation) and concurrent reduction in 
STAT3 phosphorylation by 2 h (Figure 4A). In addition, we consistently observed a second wave of 
STAT3 activation, approximately 4 h following OSM pulse treatment, despite the presence of SOCS3 
(Figures 1A-B and 4A). In OSM-pulsed SCC cells without OSMR over-expression (ME180), this STAT3 
reactivation was also detectable but was weaker and delayed (Figure 1A-B).  
 
The re-phosphorylation of STAT3 in the SW756 cells was blocked by inhibiting Golgi transport with 
monensin (Golgi-STOP) (Figure 4B), indicating a requirement for newly secreted proteins. We 
hypothesized that such proteins were IL6 family cytokines, which are strong inducers of STAT3 
phosphorylation [22]. OSM-pulsed SW756 cells secreted both OSM and IL6 over a 4 h period (Figure 
4C-D). Levels of OSM mRNA also increased, indicating de novo synthesis (Figure 4E). For both ME180 
and MS751 cells, cells transfected with OSMR and pulsed with OSM showed greater secretion of 
OSM over the following 4 h than OSM-pulsed wild-type cells (Figure 4F). However, we could not 
detect secretion of IL6 by these cells in any of the conditions tested.  
 
In both SW756 and ME180 cells, OSM pulse-stimulation also induced further expression of OSMR, 
which was detectable after 2–4 h and sustained for at least 72 h (Figure 4G-H). The induction of 
OSMR was stronger and more prolonged in the cells with baseline OSMR over-expression (SW756), 
compared with cells without baseline OSMR over-expression (ME180). In keeping with these 
observations, SW756 cells that constitutively over-expressed OSM following transfection (SW756-
pOSM) showed higher OSMR mRNA levels than wild-type SW756 cells (Figure 4I).  
 
In SW756 cells treated with a 15 min pulse of OSM (followed by OSM removal), the second wave of 
STAT3 activation at 4 h was inhibited by anti-OSM neutralizing antibody but not by anti-IL6 
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neutralizing antibody (Figure 4J and supplementary material, S4A). Inhibition of the second wave of 
STAT3 activation by the anti-OSM neutralizing antibody persisted to 24 h after the OSM pulse and 
was accompanied by inhibition of OSMR induction at 4 hours post-pulse (Figure 4K). In keeping with 
the findings using the anti-IL6 antibody, treatment of SW756 cells with exogenous IL6 (at doses 
between 100 and 400 ng/ml) did not induce STAT3 activation or expression of pro-malignant target 
genes (supplementary material, Figure S4B-C), indicating poor sensitivity of these cells to IL6. IL6R 
mRNA expression in SW756 was low and did not change after OSM treatment (supplementary 
material, Figure S4D). Unlike OSMR, IL6R (and LIFR) were not over-expressed in SCCs from multiple 
anatomical sites (supplementary material, Figure S5). In SW756 cells that had not been treated with 
OSM, the background levels of activated STAT3 were low but detectable after prolonged Western 
blot exposure (supplementary material, Figure S4E). Treatment of such cells with the anti-OSM 
neutralising antibody produced a small but discernible reduction in activated STAT3 at 24 h 
(supplementary material, Figure S4E). 
 
Anti-OSM neutralizing antibody inhibits OSM:OSMR pro-malignant signalling in SCC cells 
 
Together, the above data demonstrated a cell-autonomous feed-forward loop activated by OSM that 
induced both OSM and OSMR, thereby propagating STAT3 activation. They indicated that anti-OSM 
neutralizing antibodies would act on OSMR-overexpressing cervical SCC cells at multiple stages in the 
response to OSM, by inhibiting both the initial effects of OSM exposure and the consequent feed-
forward loop, thereby providing sustained suppression of OSM-induced pro-malignant effects. We 
therefore tested the effect of anti-OSM neutralizing antibodies on the expression of OSMR targets 
and in functional assays of angiogenesis, invasion and lung colonization (Figure 5). 
 
Anti-OSM neutralizing antibody showed dose-dependent inhibition of OSM activation of OSMR 
target genes (VEGFA, SNAI1 and TGM2) in the OSMR over-expressing cervical SCC cells SW756 and 
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CaSki (Figure 5 A-B). Whereas conditioned medium from SW756 cells treated with OSM induced 
endothelial tubule formation in an in vitro angiogenesis assay (previously shown to be due to VEGFA 
secretion [5]), conditioned medium from SW756 cells also treated with anti-OSM neutralizing 
antibody produced significantly less angiogenesis, as measured by the total length of endothelial cell 
tubules and the number of tubule junctions formed (Figure 5C-E). In SW756 cells treated with PBS 
rather than OSM, the anti-OSM neutralizing antibody again reduced tubule length and junction 
number, although the differences did not reach statistical significance (Figure 5D-E). Furthermore, 
anti-OSM neutralizing antibody inhibited the increased invasiveness induced by OSM in both SW756 
and OSC19 SCC cells (Figure 5F-G). In SW756, the antibody also significantly reduced invasiveness in 
the absence of exogenous OSM. 
 
In vivo, pre-treatment of luciferase-expressing SW756 cells with the murine ‘parental’ version of the 
anti-OSM neutralizing antibody prior to addition of exogenous OSM resulted in significant reduction 
of lung colonization following tail-vein injection, compared with cells pre-treated with IgG control 
prior to OSM (Figure 5H-I, compare purple and red lines, p=0.017; supplementary material, Figure 
S6A-D). In addition, pre-treatment with the anti-OSM neutralizing antibody also significantly reduced 
lung colonization in the absence of any exogenous OSM, compared with cells pre-treated with IgG 
control only (Figure 5H-I, compare green and blue lines, and supplementary material, Figure S6E; p = 
0.011). The lung colonisation data obtained by the In Vivo Imaging Software were confirmed using 
two independent methods: histological quantification of the area of lung tissue occupied by 
malignant cells (supplementary material, Figure S6F) and q-PCR quantification of the amount of 
human DNA in lung tissue, normalised to 45S ribosomal DNA (Supplementary material, Figure S6G). 
There were no histological differences in cell morphology or mitotic rate between the lung 
metastases in the different experimental groups.  
 
OSMR levels correlate with multiple signalling and downstream genes in SCC clinical samples 
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To test whether our findings were relevant in SCC clinical samples, we examined data from 1,254 
SCCs in TCGA. Across SCCs from cervix (n=251), head/neck (n=504) and lung (n=499), OSMR mRNA 
levels showed strong positive correlations with those of OSM, STAT3, EGFR and the downstream 
genes VEGFA and TGM2 (supplementary material, Figure S7 and Table 1). These observations were 
supported by previous evidence of an association between levels of OSMR and SNAI1 in the same 
datasets and an association between OSMR and decreased overall survival in the cervical SCCs [9].  
 
16 
 
Discussion 
 
Here we have performed the first detailed characterisation of the signalling pathways activated by 
OSM in SCC cells with OSMR over-expression. We show that the signals induced by exogenous OSM 
are mediated by OSMR and not by LIFR. We also obtained multiple lines of evidence indicating that 
OSMR over-expression produces pro-malignant effects in the absence of exogenous OSM. Forced 
expression of OSMR in cervical SCC cells with low baseline levels (ME180 and MS751) led to 
increased levels of pSTAT3 and pERK1/2 in the absence of exogenous OSM. Moreover, anti-OSM 
blocking antibodies reduced invasiveness and experimental lung metastasis in SW756 cells that had 
not been treated with OSM. Such effects could not be attributed to cross-reactivity with the murine 
system, as mouse OSM does not bind human OSMR [14] and is not inhibited by the anti-OSM 
neutralizing antibody used (unpublished data). In keeping with these findings, OSM was detectable 
in OSM-untreated SW756 cells, at both the mRNA (Figure 4E, first column) and protein levels (0.2 
pg/5x106 cells; supplementary material, Figure S3F). In addition, treatment with anti-OSM 
neutralizing antibody inhibited basal STAT3 activation in unstimulated SW756 cells (supplementary 
material, Figure S4E). Together, these observations indicate functionally significant autocrine 
OSM:OSMR interactions in SCC cells that over-express OSMR.  
 
We identified that JAKs and STAT3 were critical in inducing all the functionally significant pro-
malignant target genes previously shown to be downstream of OSM:OSMR interactions in OSMR 
over-expressing SCC cells [5, 6, 9]. STAT3 also had an important role in SCC cell experimental lung 
metastasis, which was significantly reduced following STAT3 depletion, with or without exogenous 
OSM treatment. Importantly, we also observed a second wave of STAT3 activation following OSM 
stimulation, due to a novel feed-forward mechanism involving further induction of both OSM and 
OSMR. This is, to our knowledge, the first evidence that endogenously produced OSM released by 
cancer cells in response to OSMR-STAT3 activation contributes to the pro-malignant phenotype.  
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The OSM-dependent STAT3 re-phosphorylation occurred in the presence of the negative regulator 
SOCS3, indicating the involvement of further STAT3 activating mechanisms that were unaffected by 
SOCS3. Such mechanisms may involve EGFR, as responses to IL6 in colonic adenocarcinoma cells 
included a second wave of STAT3 reactivation that was not inhibited by SOCS3, due to direct 
interactions between IL6R and EGFR [23]. As OSMR is also a receptor for cytokines in the IL6 family, 
it may serve analogous roles to IL6R in other malignancies, including SCCs. Indeed, it was recently 
shown that OSMR binds the most common form of mutant EGFR in glioblastoma multiforme cells, to 
produce a co-receptor that is required for STAT3 signalling [12]. In keeping with these findings, we 
observed a strong correlation between levels of OSMR and EGFR transcripts in SCC samples from 
multiple anatomical sites. Moreover, OSM rapidly increased levels of EGFR protein in cervical SCC 
cells without affecting transcript levels, supporting a further role for OSMR in increasing EGFR 
protein stability. 
 
Based on our in vitro observations, we reasoned that effective antibody blockade of cell surface 
OSM:OSMR interactions would inhibit both the initial effects of exogenous OSM and the 
consequences of feed-forward induction of further OSM and OSMR. In keeping with this prediction, 
anti-OSM blocking antibodies produced potent anti-malignant effects, both in the presence and 
absence of exogenous OSM. Ours is the first demonstration that these antibodies inhibit metastasis 
in relevant pre-clinical animal models. They extend previous evidence that anti-OSM blocking 
antibodies, including those used here, inhibit the paracrine effects of OSM released by carcinoma-
associated adipose tissue on breast adenocarcinoma cells [24]. The anti-OSM neutralizing antibody 
used in our experiments is safe and well tolerated in man and is presently under clinical evaluation 
as a therapy for systemic sclerosis and scleroderma [25] 
(https://clinicaltrials.gov/ct2/show/NCT02386436; 
https://clinicaltrials.gov/ct2/show/NCT03041025). 
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In conclusion, improved understanding of the biology of OSMR has indicated its importance as a 
driver of several common cancers. As a major activator of STAT3 signalling it offers the potential for 
therapeutic combination with a variety of conventional and targeted agents in current clinical use. 
We hypothesize that OSM:OSMR blocking antibodies could show clinical benefit in cervical SCCs with 
OSMR over-expression, which is seen in approximately 50% of advanced cases [9]. Further pre-
clinical investigation of the effects of OSM:OSMR blocking antibodies as single agents or in 
combination therapies for SCC is now strongly indicated. Such work should include 
immunocompetent mouse models, in which OSM:OSMR effects on local and systemic immune 
responses can be studied. 
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Table 1. Correlations between levels of OSMR and those of OSM, STAT3, EGFR, VEGFA and TGM2 
in clinical samples of cervical, head/neck and lung SCCs. 
Linear regression analysis of expression levels of OSMR versus those of OSM, STAT3, EGFR, VEGFA 
and TGM2 in cervical (n=251), head/neck (n=504) and lung (n=499) SCC samples from TCGA (r = 
correlation coefficient). 
 
Gene 
Cervical SCC 
n = 251 
Head and Neck SCC 
n = 504 
Lung SCC 
n = 499 
p value r p value r p value r 
OSM 0.049 0.124 2.1 x 10
-6
 0.199 2.6 x 10
-4
 0.157 
STAT3 2.6 x 10
-13
 0.440 < 1.0 x 10
-16
 0.354 5.6 x 10
-14
 0.316 
EGFR < 1.0 x 10
-16
 0.621 < 1.0 x 10
-16
 0.585 < 1.0 x 10
-16
 0.400 
VEGFA 7.5 x 10
-9
 0.332 2.5 x 10
-6
 0.197 4.1 x 10
-4
 0.152 
TGM2 3.3 x 10
-7
 0.315 6.3 x 10
-8
 0.226 4.0 x 10
-11
 0.279 
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Figure Legends 
 
Figure 1. Analysis of signalling pathways downstream of OSMR activation in SCC cells. 
(A) Western blots showing activation of the indicated proteins in cells with high (SW756) or low 
(ME180) levels of OSMR, treated for 15 min with OSM or vehicle (ctrl). The blot exposure times 
varied between the cell lines. (B) Densitometric quantification of the blots shown in panel A. 
Phospho-protein levels are related to total levels of the respective proteins, while total EGFR and 
STAT1 are related to β-tubulin. Changes in each cell line are referred to vehicle-treated cells. 
Accordingly, the graphs do not show the differences in baseline levels of each protein between the 
cell lines. (C-D) Western blots showing activation of STAT3 and ERK1/2 in ME180 (C) and MS751 (D) 
cells transfected with control or OSMR plasmid and treated with OSM for 15 min. The numbers 
below the blots indicate relative densitometric quantification of the corresponding phospho-protein 
levels, related to total levels of the respective proteins. The levels of OSMR transcript expression in 
ME180 and MS751 cells were determined by RT-qPCR (C-D, right). OSMR protein was not detected 
satisfactorily in ME180 cells. (E) Western Blots of the indicated proteins 30 min and 4 h following 
OSM pulse treatment (15 min) in SW756 cells transfected with siRNAs against OSMR, LIFR or non-
targeting control (siNTC). Data are presented as mean ± SEM. Transcript quantification values are 
from three independent experiments. The Western blots show data from one representative 
experiment, out of two performed. 
 
Figure 2. Expression of the pro-malignant target genes VEGFA, SNAI1 and TGM2 in SCC cells with 
high versus low levels of OSMR. 
Each panel shows RT-qPCR analysis of mRNA levels in OSM-treated SCC cells, comparing: (A) Two 
cervical SCC cells with high OSMR expression (SW756 and CaSki) versus two with low OSMR 
expression (ME180 and MS751); (B) MS751 cells transfected with OSMR over-expressing plasmid 
versus those transfected with the corresponding control plasmid; (C, D) OSMR-high cervical (C) or 
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skin and head/neck (D) SCC cells transfected with the indicated siRNAs, versus the same cells treated 
with non-targeting siRNAs (siNTC). Cells were treated with OSM for 24 h (A, C) or 48 h (B, D) prior to 
analysis. All expression values were first referenced to PBS-treated cells, then compared between 
the respective experimental groups. Key: * p < 0.05, ** p < 0.01, *** p < 0.001. Data are presented 
as mean ± SEM (n=4 for A, n=3 for B-D). 
 
Figure 3.  Effect of JAK/STAT3 inhibition on OSM pro-malignant effects in SCC cells. 
(A) Western blots showing the effects of small molecule inhibitors on activation of their target 
signalling pathways in SW756 cells treated with OSM for 30 min. (B-E) qRT-PCR analysis of VEGFA, 
SNAI1 and TGM2 mRNA levels in SCC cells, examining: (B) SW756 cells treated with OSM or vehicle 
(PBS) for 24h; (C) SW756 cells over-expressing OSM; (D, E) SW756, CaSki, OSC19 and HSC1 cells 
transduced with STAT3 siRNAs and treated with OSM for 48h, compared with cells treated with non-
targeting siRNAs (siNTC) and OSM. (F) Quantification of invasion in SW756 cells pre-treated with 
STAT3 siRNAs or siNTC and treated with OSM or PBS for 48 h. (G-H) Lung colonization in NOD-SCID 
mice following tail vein injection of SW756 cells in the presence of STAT3 siRNAs or siNTC, treated 
with OSM or vehicle (PBS) for 48 h. Luminescence images from the end point of the experiment are 
shown in (G) and the time course quantification of thoracic bioluminescent signal in H). For all 
panels, *p<0.05, **p<0.01, ***p<0.001. Data are presented as mean ± SEM (n=3 for B-E; n=5 for F; 
n=6 per group for G-H. Panel A shows data from one representative western blot, out of two 
performed. 
 
Figure 4. Induction of feed forward signalling loops by OSMR activation. 
(A, B) Western blots showing: (A) biphasic STAT3 activation and SOCS3 expression in OSM-pulsed 
SW756 cells; and (B) inhibition of STAT3 re-activation in SW756 cells by GolgiSTOP, assessed 4h after 
a 15min OSM pulse. (C-D) Levels of OSM (C) and IL6 (D) secretion by SW756 at various time-points 
after a 15 min OSM pulse, compared with untreated (Ctrl) cells. E) RT-qPCR analysis of OSM mRNA 
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levels in SW756 pulsed with OSM for 15 min. (F) Levels of OSM secretion by ME180 and MS751 cells 
over-expressing OSMR, 4 h after a 15 min OSM pulse. (G) Western blots showing OSMR levels 
following OSM pulse treatment of SW756 and ME180 cells. (H) Densitometric quantification of the 
blots in G. Changes in each cell line refer to untreated SW756 cells. (I) RT-qPCR analysis of OSMR 
transcript levels in SW756 cells constitutively over-expressing OSM . J-K) Western blots showing 
STAT3 activation in SW756 cells treated with anti-OSM (0.25 μg/ml), anti-IL6 (0.5 μg/ml) or control 
antibodies (IgG) (J); and OSMR levels and STAT3 activation in SW756 cells treated with anti-OSM or 
control (IgG) antibodies (0.25 μg/ml) (K), following a 15 min OSM pulse. For all panels, ***p<0.001. 
Data are presented as mean ± SEM (n=3 for C, D and F; n=2 for E; n=4 for I). The Western blots 
(panels A, B, G, H, J and K) show data from one representative experiment, out of two performed. 
 
Figure 5. Effect of neutralizing anti-OSM antibodies on the pro-malignant phenotype of OSMR 
over-expressing SCC cells. 
(A, B) Inhibition of OSM induction of OSM:OSMR target genes by neutralizing anti-OSM antibody in 
SW756 (A) and CaSki (B). The range of antibody concentrations was 8 ng/ml to 1 µg/ml. Cells were 
pre-treated with antibody, then with OSM for 24h. (C-E) Effects on in vitro angiogenesis of 
conditioned medium from SW756 cells treated for 48 h with OSM or vehicle (PBS) after pre-
treatment with anti-OSM or control (IgG) antibodies. VEGF and suramin were positive and negative 
controls, respectively. Panel C shows representative images (bars=100 µm), while measurements for 
total tubule length and number of junctions are in D and E, respectively. (F-G) Quantification of 
invasion of SW756 (F) and OSC19 (G) cells pre-treated with anti-OSM or control (IgG1) antibodies, 
then treated for 48 h with OSM or vehicle (PBS). (H-I) Lung colonization in NOD-SCID mice following 
tail vein injection of SW756 cells treated for 48 h with OSM or vehicle (PBS), following pre-treatment 
with anti-OSM or control (IgG) antibodies. Luminescence images from the end point of the 
experiment are shown in (H) and time-course quantification of thoracic bioluminescent signal in (I). 
For all panels, *p<0.05, **p<0.01, ***p<0.001. Data represent mean ± SEM (n=4 for A-B; n=3 for D-E; 
26 
 
n=5 for F-G; n=6 per group for H-I). Panel C shows representative pictures from one experiment, out 
of three performed. 
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Supplementary Materials and methods 
Cell invasion assay 
Invasion assays were performed in Boyden chambers, using the Cultrex basement membrane extract 
(BME) cell invasion assay (R&D Systems, Minneapolis, MN, USA). In brief, 0.5×105 SW756 or 0.25×105 
OSC19 cells were subjected to different treatments (OSM stimulation, gene depletion or antibody 
treatment), starved for 24 h in serum-free medium, then seeded in the BME-coated upper chamber. 
The lower chamber was filled with medium supplemented with 10% FBS. After 24 hours, the cells 
that had invaded through the basement membrane were stained with Calcein-AM. Standard curves 
for each cell line were used to convert fluorescence values into cell numbers. All experiments were 
performed at least in triplicate and the mean values used to indicate invasion rates. 
 
Angiogenesis assay 
We measured endothelial tubule formation using co-cultures of human umbilical vein endothelial 
cells and primary human fibroblasts (V2a assay; Cellworks, San Jose, CA, USA). Forty-eight hours 
after cell seeding, the medium was replaced by conditioned medium from SW756 cells subjected to 
different treatments, or by control medium from untreated SW756 cells. Each type of medium was 
replaced every two days, for a duration of 14 days. Each conditioned medium sample was first 
clarified and concentrated using Amicon Ultra-4 Centrifugal Filter Units (Merck Millipore, Billerica, 
MA, USA), then re-suspended in V2a growth medium (Cellworks). Suramin (1 mM), an inhibitor of 
angiogenesis, and VEGFA (2 μg/ml) were used as negative and positive controls, respectively. To 
visualize the endothelial tubules, cells were fixed in cold ethanol (70%), stained with anti-human 
CD31 primary antibody and goat anti-mouse IgG-AP secondary antibody, then treated with BCIP/NBT 
substrate, according to the manufacturer’s instructions for the V2A assay (all reagents from 
Cellworks). Total tubule length and the number of junctions formed were quantified using the 
AngioSys 2.0 Image Analysis Software (Cellworks). 
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Verification of In Vivo Imaging Software data 
The data obtained by the In Vivo Imaging Software was confirmed using two independent methods: 
histology and RT-PCR of human DNA.  
 
For histological analyses, haematoxylin and eosin stained histological lung sections were scanned at 
20X using a Nanozoomer 2.0RS (C10730) (Hamamatsu Photonics K. K., Hamamatsu City, Japan). For 
determination of the area of lung affected by neoplastic aggregates, the scanned histological section 
was analysed using NDP.view2 viewing software (Hamamatsu Photonics K. K.). The ‘freehand region’ 
tool was used to measure the total scanned lung area, and to measure areas occupied by individual 
foci of neoplastic cells. The percentage of the analysed lung area affected by tumour was 
subsequently calculated from the measured values. 
 
For quantification of human DNA in murine lungs, DNA was extracted from fixed lungs using the 
QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany) and quantitative real time PCR was 
performed as described in Materials and Methods by using primers for human Alu repetitive 
sequences (Forward primer: ACGCCTGTAATCCCAGCACTT; reverse primer: 
TCGCCCAGGCTGGAGTGCA) [26]. DNA ratios were normalized to human and mouse 45S ribosomal 
DNA (Forward primer: CGCGGTTCTATTTTGTTGGT ; reverse primer: CGGTCCAAGAATTTCACCTC). 
 
Bioinformatics analysis of next generation sequencing data 
 
Computational analysis and statistical testing were conducted using the R statistical programming 
language. Filtered and log2 normalized RNA expression data were downloaded from the Genome 
Data Analysis Centre Firehose database (run: stddata__2015_06_01) for each gene of interest from 
the cervical cancer (CESC), head and neck SCC (HNSCC) and lung SCC (LUSC) collections. Data 
downloads were performed using the FirebrowseR database access R package. Correlation testing 
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for associations between expressed genes was performed using the cor.test function in R to 
calculate the correlation coefficient (r) and test for significant deviation from no correlation. Plotting 
of correlation data was performed using the ggplot2 R package. 
 
Statistics 
 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, 
CA, USA). For comparisons between groups we used Student’s t-test and ANOVA, with post hoc 
analysis by the Student–Newman–Keuls’ test. A p value of <0.05 was considered statistically 
significant. Data were presented as mean ± SEM. Time courses for the development of lung 
metastases in vivo were compared using linear mixed effects modelling, implemented in R via the 
lme4 package. 
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Supplementary Table S1. SCC cell lines used and their culture conditions 
Cell line Site of origin Culture conditions Reference / Supplier 
CaSki Cervix GMEM (Sigma-Aldrich, St. Louis, USA ) ATCC (Middlesex, UK) 
SW756 Cervix GMEM ATCC 
ME180 Cervix GMEM ATCC 
MS751 Cervix GMEM ATCC 
SCC-25 Tongue 
FAD (DMEM: Ham’s F12, 3:1; Thermo 
Fisher Scientific, Waltham, MA, USA) + 
3T3 irradiated feeders 
Reinwald and Becket 
[32]  
SCC-15 Tongue FAD + 3T3 irradiated feeders 
Reinwald and Becket 
[32]  
OSC-19 Tongue DMEM: Ham’s F12, 1:1 JCRB cell bank 
CAL 27 Tongue DMEM ATCC 
FaDu Pharynx 
MEM (GE Healthcare, Little Chalfont, 
UK) 
ATCC 
Detroit 562 Pharynx MEM ATCC 
SCC-4 Floor of mouth FAD + 3T3 irradiated feeders 
Reinwald and Becket 
[32]  
SCC-12B.2 Skin FAD + 3T3 irradiated feeders 
Reinwald and Becket 
[32]  
HSC-1 Skin GMEM JCRB cell bank 
SCC-13 Skin 
FAD + 1.36 ng/ml triiodo-L-thyronine, 
5µg/ml insulin, 0.5 µg/ml 
hydrocortisone, 18 nM adenine and 
10 ng/ml EGF 
Reinwald and Becket 
[32] 
SJG032 Mouth FAD + 3T3 irradiated feeders Hayes et al. [33] 
HN5 Head and neck DMEM Rusnak et al.  [34] 
A-253 
Submaxillary 
salivary gland 
DMEM ATCC 
 
Key: ATCC - American Type Culture Collection, JCRB - Japanese Collection of Research Bioresources, 
DMEM - Dulbecco's Modified Eagle Medium, GMEM - Glasgow’s Modified Eagle Medium, MEM - 
Minimum Essential Medium 
2 
 
 
Supplementary Table S2. siRNA pools used for gene depletion 
 
Gene target ON-TARGETplus SMART pool Sequence of individual duplexes 
Non-targeting 
control 
D-001810-10-20 
1: UGGUUUACAUGUCGACUAA 
2: UGGUUUACAUGUUGUGUGA 
3: UGGUUUACAUGUUUUCUGA 
4: UGGUUUACAUGUUUUCCUA 
LIFR L-008017-01-0020 
1: AGAACAAACCAAACGAUUA 
2: GCAAUAUCUAGCAGCGUUA 
3: GAGAGUAACAACACGGGAA 
4: CGGAAACGAGAAUGGAUUA 
OSMR L-008050-00-0020 
1: AGUCUUGGCUGAACGUUUA 
2: UUUGAGAACUUGACCUAUA 
3: CCUCGAUGCUGAUUCAUAU 
4: AAUCUGAGCUCCCUUUGGA 
STAT3 L-003544-00-0020 
1: GAGAUUGACCAGCAGUAUA 
2: CAACAUGUCAUUUGCUGAA 
3: CCAACAAUCCCAAGAAUGU 
4: CAACAGAUUGCCUGCAUUG 
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Supplementary Table S3. Primers used for qPCR 
 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Reference / 
Supplier 
Co
m
pl
em
en
ta
ry
 D
N
A 
pr
im
er
s 
EGFR NM_005228 NM_005228 
Sigma 
KiCqStart™ 
(Sigma, St. 
Louis, USA) 
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 
Vandesompele 
et al. [21]  
LIFR Hs_LIFR_1_SG Hs_LIFR_1_SG 
QuantiTect 
(QIAGEN, 
Crawley, UK) 
OSMR Hs_OSMR_1_SG Hs_OSMR_1_SG 
QuantiTect 
(QIAGEN) 
RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA 
Vandesompele 
et al. [21]  
SNAI1 TCGGAAGCCTAACTACAGCGA AGATGAGCATTGGCAGCGAG PrimerBank 
STAT1 NM_007315 NM_007315 
Sigma 
KiCqStart™ 
STAT3 Hs_STAT3_1_SG Hs_STAT3_1_SG 
QuantiTect 
(QIAGEN) 
STAT5A NM_003152 NM_003152 
Sigma 
KiCqStart™ 
STAT5B NM_012448 NM_012448 
Sigma 
KiCqStart™ 
STAT6 NM_001178078 NM_001178078 
Sigma 
KiCqStart™ 
TGM2 Hs_TGM2_1_SG Hs_TGM2_1_SG 
QuantiTect 
(QIAGEN) 
VEGFA NM_001204384 NM_001204384 
Sigma 
KiCqStart™ 
4 
 
YWHAZ ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 
Vandesompele 
et al. [21]  
Ge
no
m
ic
 D
N
A 
pr
im
er
s 
ACTBprom CTGATGCCACAATCACCCCT GTAATGTATTAACTTCCTGGCCATT 
Groves et al. 
[35]  
GAPDHprom CGGCTACTAGCGGTTTTACG AAGAAGATGCGGCTGACTGT 
Groves et al. 
[35]  
MYOGprom GGAGAAAGAAGGGGAATCACAT GATAAATATAGCCAACGCCACA 
Groves et al. 
[35]  
OSMR GACAACTTCGCAGCCCATC GTAGCCCAGCCAAGCAAAC Own design 
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Supplementary Table S4. Antibodies used for Western blotting 
Target  
Antibody 
catalogue 
number 
Supplier Host species Dilution 
AKT 9272 
Cell Signaling 
Technology 
(Danvers, MA, 
USA) 
rabbit 1 : 1000 
EGFR ab52894 
Abcam 
(Cambridge, UK) 
rabbit 1 : 100000 
ERK 610124 
BD Biosciences 
(San Jose, CA, 
USA) 
mouse 1 : 1000 
LIFR sc-659 
Santa Cruz 
Biotechnology 
(Dallas, TX, USA) 
rabbit 1 : 1000 
OSMR β sc-30010 
Santa Cruz 
Biotechnology 
rabbit 1 : 500 
Phospho-AKT 
(Ser473) 
9271 
Cell Signaling 
Technology 
rabbit 1 : 1000 
Phospho-EGFR 
(Tyr1068) 
ab32430 Abcam rabbit 1 : 10000 
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
9101 
Cell Signaling 
Technology 
rabbit 1 : 1000 
Phospho-STAT1 
(Tyr701) 
7649 
Cell Signaling 
Technology 
rabbit 1 : 1000 
Phospho-STAT3 
(Tyr705) 
9145 
Cell Signaling 
Technology 
rabbit 1 : 2000 
Phospho-STAT5 
(Tyr694) 
9359 
Cell Signaling 
Technology 
rabbit 1 : 1000 
SOCS3 sc-7009 
Santa Cruz 
Biotechnology 
goat 1 : 1000 
6 
 
STAT1 9172 
Cell Signaling 
Technology 
rabbit 1 : 1000 
STAT3 9139 
Cell Signaling 
Technology 
mouse 1 : 1000 
STAT5  610191 BD Biosciences mouse 1 : 1000 
β actin ab6276 Abcam mouse 1 : 150000 
β tubulin ab6046 Abcam rabbit 1 : 10000 
Rabbit P044801 
Dako (Glostrup, 
Denmark) 
goat 1 : 2000 
Mouse P044701 Dako goat 1 : 2000 
Goat P044901 Dako rabbit 1 : 1000 
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Supplementary Figure legends 
 
Figure S1. OSMR copy number and expression in SCC cell lines 
(A-F) Quantification of OSMR relative gene copy number (A), mRNA (B) and protein (C-F) levels in a 
panel of 17 SCC cell lines from different anatomical sites, plus three primary cultures of basal-type 
normal cervical squamous cells (NCx). OSMR relative gene copy number (A) was determined by q-
PCR, referenced to normal cervical cells with one copy of the OSMR gene per haploid genome 
(NCx6). OSMR mRNA expression (B) was also determined by RT-qPCR, referenced to CaSki cells, 
which had previously been shown to over-express OSMR at 3.4-fold greater levels than a pool of four 
independent cultures of basal-type normal cervical squamous cells [8]. Protein levels were 
determined by Western blotting (C-F), with densitometric quantification using Ponceau staining (C) 
or beta-actin (E) as loading controls and CaSki as the reference sample. Data in panels A, B, D and F 
are presented as mean ± SEM (n=3). Western blots (panels C and E) show data from one 
representative experiment, out of two performed. (G, H) Correlation testing for associations 
between OSMR protein levels across the 17 SCC cells and OSMR relative gene copy number (G) or 
mRNA expression (H). R2 = coefficient of determination. 
 
Figure S2. OSMR over-expression in SCC cells enhances responsiveness to OSM 
(A) Flowchart summary of the OSM pulse procedure. (B) Western Blots showing activation of the 
indicated proteins in cells with high (SW756) or low (ME180) levels of OSMR, at various time points 
following a 15 min pulse with OSM or vehicle (ctrl). (C) RT-qPCR analysis of EGFR mRNA levels in 
SW756 cells treated with OSM for 24 and 48 hours. (D-F) Western Blots showing rapid activation of 
STAT3 (D-F) and ERK (F) by OSM (continuous treatment at 10 ng/ml) in OSC19 (D), HSC1 (E) and high- 
and low- OSMR cervical SCC cells (F). (G) Western Blots showing activation of STAT3 after 30 min of 
100 ng/ml LIF in SW756 cells. (H) Western Blots of the indicated proteins 30min and 4h following 
OSM pulse treatment (15 min) in ME180 cells transfected with siRNAs against OSMR, LIFR or non-
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targeting control (siNTC). (I) RT-qPCR analysis of mRNA levels of OSMR and LIFR in ME180 cells 
transfected with siOSMR or siLIFR. J-K) RT-qPCR analysis of VEGFA, SNAI1 and TGM2 mRNA levels in 
OSC19 (J) and HSC1 (K) cells treated with OSM for 48 h, compared with PBS-treated controls. L-M) 
RT-qPCR analysis of mRNA levels of OSMR (L) and LIFR (M) in SW756, CaSki, OSC19 and HSC1 cells 
transfected with siOSMR (L) or siLIFR (M). Key: siNTC: non-targeting control siRNAs; KD: knock-down. 
** p < 0.01, *** p < 0.001. Data are presented as mean ± SEM (n=2 for C, n=4 for J-K; n=3 for I, L-M). 
Western blots (panels B, D-H) show data from one representative experiment, out of two 
performed. 
 
Supplementary Figure S3. JAK2 and STAT3 mediate the pro-malignant effects of OSM:OSMR 
interactions 
(A-E) SW756 cell growth curves in the presence of different small molecule inhibitors at the 
indicated concentrations. Growth was determined by MTT assay and normalised to levels at day 1. F) 
ELISA measurements of OSM secretion by SW756 cells transfected with control or OSM over-
expressing plasmid. (G) RT-qPCR analysis of VEGFA, SNAI1 and TGM2 mRNA levels in SW756 cells 
transfected with control (pCtrl) or OSM over-expressing (pOSM) plasmid. (H-I) Western Blots 
showing lack of specific STAT3 inhibition in SW756 by the small molecule inhibitors S3i-201 (H) and 
Stattic (I) at the indicated concentrations. The white line in H indicates non-contiguous lanes from 
the same membrane. (J) RT-qPCR analysis showing STAT3, STAT1, STAT5A, STAT5B and STAT6 mRNA 
levels after SW756 cell transfection with siSTAT3, compared with cells treated with non-targeting 
control siRNAs. K-N) RT-qPCR analysis of STAT3 mRNA levels in SW756, CaSki, OSC19 and HSC1 cells 
transfected with non-targeting control siRNAs (siNTC) or siSTAT3. O) RT-qPCR analysis of VEGFA, 
SNAI1 and TGM2 mRNA levels in SW756 cells pre-treated with control (siNTC) or STAT3 siRNAs, then 
treated with vehicle (PBS) or OSM and subsequently used in the in vivo experiment shown in Figure 
3 and in panels P, Q and R of this Figure. (P, Q) Luminescent images (P) and quantification of the 
thoracic bioluminescent signal (Q) of NOD-SCID mice 1 h post tail-vein injection of SW756 cells pre-
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treated with control (NTC) or STAT3 siRNAs, followed by OSM or PBS treatment, in the in vivo 
experiment shown in Figure 3. There is even delivery of SW756 cells across the various groups. (R) 
Representative images of lung tissue at the end point of the in vivo experiment shown in Figure 3G, 
H. Scale bar: 500 µm. * p < 0.05, ** p < 0.01, *** p < 0.001. Data are presented as mean ± SEM (n=3 
for A-F; n=5 for G; n=2 for J; n=6 per group for P-R). Western blots (panels H and I) show data from 
one representative experiment, out of two performed. Key: KD: knock-down; siNTC: non-targeting 
control siRNAs. 
 
Figure S4. OSM induces a feed-forward loop in SCC cells, which prolongs STAT3 activation 
(A) Western blots showing STAT3 activation in SW756 cells treated with anti-OSM (1 μg/ml), anti-IL6 
(2.5 μg/ml) or control (IgG) (1 μg/ml) antibodies, following a 15 min OSM pulse. (B) Western blot 
showing lack of activation of STAT3 after 30 min by IL6 in SW756 cells. (C) RT-qPCR analysis of 
VEGFA, SNAI1 and TGM2 mRNA levels in SW756 cells treated with IL6 (100 ng/ml) for 48 h, 
compared with PBS-treated controls. (D) RT-qPCR analysis of IL6R mRNA levels in SW756 cells 
treated with OSM (10 ng/ml), compared with PBS-treated controls. E) Western Blots showing STAT3 
activation in SW756 cells treated with PBS, anti-OSM or control (IgG) antibodies (0.25 μg/ml) for 24 
h. Data are presented as mean ± SEM (n=3 for C-D). Western blots (panels A-B and E) show data 
from one representative experiment, out of two performed. 
 
Figure S5. IL6R and LIFR are not over-expressed in SCCs from multiple sites 
Transcript levels of IL6R (left column) and LIFR (right column) in SCC versus normal tissue from 
multiple anatomical sites. Data were derived from published gene expression profiles of cervix [27] 
(A,B), oral cavity [28] (C,D), tongue [29] (E,F), vulva [30] (G,H) and skin [31] (I,J). The number of 
samples analysed is indicated in each panel. 
 
Figure S6. Anti-OSM neutralising antibody inhibits OSM:OSMR pro-malignant signalling in SCC cells. 
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(A) RT-qPCR analysis of VEGFA, SNAI1 and TGM2 mRNA levels in SW756 cells pre-treated with 
control IgG or antibody against OSM, followed by 48 h treatment with OSM or PBS, and 
subsequently used in the in vivo experiment shown in Figure 5 and this Figure. (B, C) Luminescent 
images (B) and quantification of the thoracic bioluminescent signal (C) of NOD-SCID mice 1 h post 
tail-vein injection of SW756 cells pre-treated with control IgG or antibody against OSM, followed by 
48 h treatment with OSM or PBS, in the in vivo experiment shown in Figure 5. There is even delivery 
of SW756 cells across the various groups. (D) Representative images of lung tissue (left) and whole 
lungs (right) at the end point of the in vivo experiment shown in Figure 5H-I. Scale bars: 500 µm (left) 
and 1 mm (right). (E) Time-course quantification of thoracic bioluminescent signal in NOD-SCID mice 
following tail vein injection of SW756 cells treated for 48 h with vehicle (PBS), following pre-
treatment with anti-OSM or control (IgG) antibodies, from the in vivo experiment shown in Figure 5. 
The Figure has been extracted from Figure 5I, for clarity. Data are presented as mean ± SEM (n=6 per 
group for A-E). (F, G) Linear regression analysis of thoracic bioluminescent signal for each mouse at 
the end of the experiment, versus quantification of lung colonization by histological analysis (F, n=7) 
and qPCR quantification of human DNA (G, n=24). In each plot, Spearman correlation coefficient (r) 
and p values are shown. 
 
Figure S7. Correlations between levels of OSMR and multiple signalling and downstream genes in 
clinical samples of cervical SCCs 
Linear regression analysis of expression levels of OSMR versus those of OSM, STAT3, EGFR, VEGFA 
and TGM2 in cervical SCC samples from TCGA (n=251). For each gene, correlation coefficient (r) and 
p values are shown. 
 







